4.8 Article

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.2120976119

Keywords

SARS-CoV-2; monoclonal therapy; neutralizing antibody; cryoelectron microscopy; variants of concern

Funding

  1. Toscana Life Sciences, through the European Research Council advanced Grant [787552]
  2. European Union's Horizon 2020 research and innovation program [653316]
  3. Italian Ministry of Health [COVID-2020-12371817]
  4. Scripps Research Institute
  5. Institut Pasteur
  6. Urgence COVID-19 Fundraising Campaign of Institut Pasteur
  7. ANRS
  8. Vaccine Research Institute [ANR-10-LABX-77]
  9. Labex IBEID [ANR-10-LABX-62-IBEID]
  10. ANR/FRM Flash Covid PROTEO-SARS-CoV-2
  11. IDISCOVR
  12. Bill & Melinda Gates Foundation [OPP1170236/INV-004923]
  13. European Research Council (ERC) [787552] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

As the COVID-19 pandemic continues, highly potent monoclonal antibodies are needed to combat SARS-CoV-2 variants of concern. This study evaluates the efficacy of mAb J08 against these variants and investigates the binding details using cryo-EM and X-ray crystallography. The results demonstrate that mAb J08 has strong affinity against most variants and binds at a specific location on the receptor binding domain, away from the mutation sites. These findings further support the use of mAb J08 as a monoclonal therapy in ongoing clinical trials.
As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for highly potent monoclonal antibodies (mAbs) that are resistant against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs). Here, we evaluate the potency of the previously described mAb J08 against these variants using cell-based assays and delve into the molecular details of the binding interaction using cry-oelectron microscopy (cryo-EM) and X-ray crystallography. We show that mAb J08 has low nanomolar affinity against most VoCs and binds high on the receptor binding domain (RBD) ridge, away from many VoC mutations. These findings further validate the phase II/III human clinical trial underway using mAb J08 as a monoclonal therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available